Biotherapeutics can be used to treat numerous diseases and made headlines in the midst of the COVID-19 pandemic as a potentially life-saving treatment against SARS-CoV-2 infection. Market analysis suggests that global demand for biotherapeutic products will continue to increase at a rate that exceeds companiesâ€™ current manufacturing capabilities. Because biotherapeutics are produced in complex biological systems, efficient purification strategies are critical to overcoming manufacturing limitations and meeting the needs of patients.
The development of versatile affinity and non-affinity resins is important to improving biotherapeutic manufacturing. Affinity chromatography resins based on the variable antigen-binding region (VHH) of camelid heavy-chain only antibodies can provide high selective affinity for a broad range of biotherapeutic targets, thus improving purification protocols. Likewise, varied non-affinity resins can further improve biotherapeutic purification and yield. This whitepaper from Thermo Fisher Scientific highlights the versatility of affinity and non-affinity resins and explores how they can support purification of diverse biotherapeutics.
- Why affinity and non-affinity chromatography are important for the purification of biotherapeutics
- How affinity ligands enable specific capture and purification of varied types of biotherapeutics
- How decisions around selecting a non-affinity ligand can affect the purification and manufacturing process